Sign in
Active, not recruitingNo phase

Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve

Key facts

Who runs it
Edwards Lifesciences
Where
Ann Arbor, Athens, Atlanta, Carmel, Durham, Milwaukee, Nashville, New York, Newport Beach, Orlando, Palo Alto, Philadelphia, Pittsburgh, Rochester, Salt Lake City, and St Louis, United StatesSee the 20 sitesAlso in 3 other countries, 14 sites
Trial code
Status
Active, not recruiting
People taking part
504 people enrolled
Started
11 Jan 2023
Expected to end
Dec 2035
Type of study
Observational
Treatments tested
  • MITRIS RESILIA Mitral Valve, Model 11400M
Record updated
22 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • 18 years or older at the time of informed consent
  • Has a dysfunctional native or prosthetic mitral valve and requires mitral valve replacement surgery
  • Provides written informed consent
  • Willingness to follow protocol requirements

Who cannot take part

  • Active endocarditis 3 months prior to the procedure
  • High predicted risk of mortality prior to procedure; Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) score of > 8 or; Surgeon estimated risk of mortality of > 8
  • Stage 4 renal disease or requiring dialysis
  • Less than 2-year life expectancy due to non-cardiovascular life-threatening disease

Where in United States

Also in 3 other countries, 14 sites

  • University of MichiganAnn Arbor, United States
  • Piedmont Heart InstituteAthens, United States
  • Piedmont Heart InstituteAtlanta, United States
  • Ascension St. Vincent Heart CenterCarmel, United States
  • Duke University Medical CenterDurham, United States
  • Aurora St. Luke's Medical CenterMilwaukee, United States
  • Ascension Saint ThomasNashville, United States
  • TriStar Centennial Medical centerNashville, United States
  • Columbia University Irving Medical CenterNew York, United States
  • Mount Sinai HospitalNew York, United States
  • Weill Cornell MedicineNew York, United States
  • Hoag Memorial Hospital PresbyterianNewport Beach, United States
  • AdventHealth OrlandoOrlando, United States
  • Stanford UniversityPalo Alto, United States
  • Hospital of the University of PennsylvaniaPhiladelphia, United States
  • Allegheny General HospitalPittsburgh, United States
  • UPMC Presbyterian ShadysidePittsburgh, United States
  • Mayo Clinic - RochesterRochester, United States
  • University of UtahSalt Lake City, United States
  • Washington University (Barnes-Jewish Hospital)St Louis, United States

About the trial

What the trial wants to find out

Collect real-world data on acute and long-term safety and performance of the MITRIS RESILIA Mitral Valve, Model 11400M, in subjects requiring replacement of their native or prosthetic mitral valve with or without concomitant procedures.

The group in the trial

  • Patients requiring replacement of their native or prosthetic mitral valve

    Treatment: MITRIS RESILIA Mitral Valve, Model 11400M

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Global Study Designed to Collect Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
Record updated
22 May 2026